 CARLSBAD, Calif., Nov. 01, 2022 GLOBE NEWSWIRE -- Pardes Biosciences, Inc. NASDAQ: PRDS, a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases i.e., COVID-19, announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 8:00 a.m. GMT 12:00 a.m. PT. 